Vaccination against tuberculosis

Enferm Infecc Microbiol Clin. 2018 Dec;36(10):648-656. doi: 10.1016/j.eimc.2018.02.006. Epub 2018 Apr 5.
[Article in English, Spanish]

Abstract

BCG (Bacille Calmette-Guérin) vaccination is included in the immunization schedule for tuberculosis endemic countries with a global coverage at birth close to 90% worldwide. BCG was attenuated from Mycobacterium bovis almost a century ago, and provides a strong protection against disseminated forms of the disease, though very limited against pulmonary forms of tuberculosis, responsible for transmission. Novel prophylactic tuberculosis vaccines are in clinical development either to replace BCG or to improve its protection against respiratory forms of the disease. There are limitations understanding the immunological responses involved and the precise type of long-lived immunity that new vaccines need to induce. MTBVAC is the first and only tuberculosis vaccine candidate based on live-attenuated Mycobacterium tuberculosis in clinical evaluation. MTBVAC clinical development plans to target tuberculosis prevention in newborns, as a BCG replacement strategy, and as secondary objective to be tested in adolescents and adults previous vaccinated with BCG.

Keywords: BCG; MTBVAC; Tuberculosis vaccine; Vacuna tuberculosis.

MeSH terms

  • BCG Vaccine* / immunology
  • Clinical Trials as Topic
  • Forecasting
  • Humans
  • Treatment Outcome
  • Tuberculosis / prevention & control*
  • Vaccination* / statistics & numerical data

Substances

  • BCG Vaccine